Nasdaq
$1.39▲ 2.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $160.8MShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 1d agoPre-market26.10.23 22:156-KKey event#●●●#●●●#●●●
NovaBridge BiosciencesBullish
NovaBridge Biosciences presented clinical data from the ongoing Phase 1 trial of 'ragistomig', a bispecific antibody targeting PD-L1 and 4-1BB, at the ESMO Congress 2026 on October 23, 2026. The presentation, conducted by partner ABL Bio, focused on the dose optimization of the drug candidate.…more
$1.39+2.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 05:154Ownership
NovaBridge Biosciences
Insider Woo Ian Ying of NovaBridge Biosciences filed a Form 4 on October 15, 2026, reporting a change in beneficial ownership of securities. This filing serves as the official record of the insider's equity transaction.…more
$1.39+2.21%vs prev closeView filingShare - 10.13Pre-market26.10.13 20:006-KKey event
NovaBridge Biosciences
NovaBridge Biosciences' subsidiary, Visara, has entered into an exclusive worldwide license agreement with Wuhan Hiteck Biological Pharma for the development and commercialization of the neurotrophic keratitis therapy VIS-102. Under the terms, Visara will pay $7.0 million in upfront and near-term milestone payments, with up to $104.0 million in additional milestone payments and tiered royalties based on future clinical and commercial performance.…more
$1.39+2.21%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5m agoClosed26.10.25 20:00#●●●#●●●
NovaBridge Reports Positive Phase 1b Data for Givastomig
NovaBridge Biosciences presented mature Phase 1b clinical data for its gastroesophageal cancer candidate at ESMO 2026. The company is advancing toward registrational Phase 3 trials following positive efficacy results and alignment with the FDA.…more
$1.39+2.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoPre-market26.10.20 20:00
●●●●●●●● ●●●●● ●●●●●●
NovaBridge's subsidiary Visara has secured an exclusive option to acquire the ocular surface squamous neoplasia treatment candidate YOL104-2. As financial terms were not disclosed and the asset remains in development, this is considered a neutral development.…more
$1.39+2.21%vs prev close - 10.13Pre-market26.10.13 20:11
●●●●●●●● ●●●●● ●●●●●●
Wuhan Hiteck has entered into an exclusive worldwide licensing agreement, excluding Greater China, with NovaBridge subsidiary Visara for its neurotrophic keratitis drug candidate HT006.2.2. Hiteck will receive an upfront payment along with potential milestone payments and tiered royalties based on future commercial success.…more
$1.39+2.21%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report